FDA Approves STEGLUJAN — Merck Sharp & Dohme LLC

# FDA Approves Merck's STEGLUJAN Combination Therapy for Type 2 Diabetes Merck Sharp & Dohme LLC received FDA approval for STEGLUJAN (ertugliflozin and sitagliptin), a dual-mechanism oral combination therapy designed to address the competitive type 2 diabetes market where fixed-dose combinations are increasingly preferred for improved patient compliance and efficacy. The approval positions Merck to capture additional market share in the antidiabetic segment, particularly against other SGLT2 inhibitor and DPP-4